Fig. 5: TFE3 contributes to the malignant progression of GBM. | Nature Communications

Fig. 5: TFE3 contributes to the malignant progression of GBM.

From: Lysine-arginine imbalance overcomes therapeutic tolerance governed by the transcription factor E3-lysosome axis in glioblastoma

Fig. 5: TFE3 contributes to the malignant progression of GBM.The alternative text for this image may have been generated using AI.

A Representative images of tissue sections immunostained with TFE3 antibody and quantification of TFE3-positive cells. Normal tissue (n = 3 biological replicates), Grade 2 (n = 5 biological replicates), Grade 3 (n = 5 biological replicates), and Grade 4 (n = 10 biological replicates) sections from independent patients. Scale bars, 50 µm. B Correlation analysis of the progression-free survival of glioma patients and their percentage of TFE3-positive cells from (A). C Kaplan–Meier survival curves of glioma patients bearing higher (red) or lower (black) percentages of TFE3-positive cells (relative to the average percentage of TFE3-positive cells) from (A). D, E Kaplan–Meier survival curves of nude mice transplanted with the TFE3-WT (black) and TFE3-KO (red) TGS04 cells (D), or control (black) and TFE3-OE (red) KGS22 cells (E). n = 5 mice per group. Data are presented as the means ± SD. Statistical comparison (A) using a one-way ANOVA. Statistical comparison (B) using Pearson correlation analysis. Statistical comparison (C–E) using Kaplan–Meier method with the log-rank test. Source data are provided with this paper.

Back to article page